Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Ulf LindströmKarin BengtssonTor OlofssonDaniela Di GiuseppeBente GlintborgHelena Forsblad-d'EliaLennart T H JacobssonJohan AsklingPublished in: Annals of the rheumatic diseases (2021)
As used in clinical practice in SpA, secukinumab appears to be associated with a higher risk of AU, compared with the monoclonal TNFi and a similar risk compared with etanercept.